Ahead of the Bell: Amgen clotting drug

Interactive Investor: "WASHINGTON (AP) - Federal health advisers on Wednesday will vote on whether an experimental biotech drug from Amgen should be approved to treat a blood-clotting disorder.
The Food and Drug Administration said on Monday Amgen's drug Nplate showed a range of adverse reactions, from bone-marrow abnormalities to blood clots, in company studies."